Introduction
============

As of January 2018, more than 300 human papillomavirus (HPV) genotypes are listed in the PAVE database ^[1](#fn01){ref-type="fn"}^ ([@B112]). HPVs have ∼8 kb circular double stranded DNA genomes, do not generally infect heterologous hosts and exhibit a preference for infecting either mucosal or cutaneous epithelia. Mucosal HPVs are generally transmitted by sexual contact and mucosal infections with α-genus HPVs are the most common sexually transmitted disease with a prevalence of 70 million cases and an annual incidence of 14 million new transmissions in the United States ([@B16]). Mucosal HPVs mostly include members of the α-genus. Clinically, α-HPVs can be designated either as "low-risk" or "high-risk." Low-risk α-HPV infections trigger benign genital warts, whereas high-risk α-HPVs cause intraepithelial lesions that can undergo malignant progression. Almost 100% of cervical carcinoma are caused by high-risk HPVs and infections with these viruses also contribute to a large percentage of anogenital tract as well as oral cancers ([@B101]). Globally, high-risk α-HPVs infections cause approximately 5% of all human cancers. Despite the availability of efficacious prophylactic vaccines for the most abundant high-risk α-HPVs, there will be approximately 4,170 cervical cancer deaths in 2018 in the United States alone, which means that approximately every 2 h one woman will succumb to cervical cancer ([@B103]). Because cancers arise years to decades after the initial infection, a significant impact of these prophylactic vaccines on cervical cancer rates is not expected for another 20 years ([@B38]; [@B102]). Unfortunately, there are no antiviral compounds to combat HPV infections ([@B47]).

Cutaneous HPVs include the β-, γ-, μ-, and ν-genera and some α-HPVs also have a preference for infecting cutaneous epithelia. Cutaneous HPV infections are very frequent and have been linked to development of warts, actinic keratosis, keratoacanthoma, psoriasis, and non-melanoma skin cancers. In Australia, up to 24% of 16- to 18-year-olds have skin warts ([@B58]). The prevalence of actinic keratosis in the United States is ∼20% and resulted in 47 million dermatology visits in 2006 ([@B30]). Keratoacanthoma are low grade, rapidly growing skin tumors that, unlike squamous cell carcinomas, are derived from cells located in the hair follicle. Cutaneous HPV genomes are readily detected in hair follicle cells harvested by plucking hair, and a high viral load is a predictor of cancer development ([@B85]). Keratoacanthoma mostly occur in sun-exposed skin in middle aged patients. The incidence has been estimated at approximately 1:1,000 ([@B22]). Cutaneous HPVs have also been frequently detected in psoriasis patients ([@B66]). In patients suffering from a rare inherited disease, *epidermodysplasia verruciformis* (EV), and in the rapidly increasing population of chronically immune-suppressed individuals, such as organ transplant patients, lesions caused by cutaneous HPV infections can progress to cutaneous squamous cell carcinomas (cSCCs) ([@B89]; [@B87]; [@B85]). Indeed, cSCCs arising in EV patients were the first human tumors that were conclusively linked to HPV infections. More recently, β- and γ-HPV genomes have also been detected at mucosal sites, suggesting the possibility that these viruses may also infect mucosal epithelia ([@B12]; [@B44]; [@B104]).

The incidence of cSCCs in the general population has been linked to UV exposure and is rising rapidly with more than 700,000 cases and 8,000 deaths yearly in the United States ([@B3]; [@B29]). The estimated annual costs for cSCC treatments in the United States are at \$3.8 billion ([@B43]). Whether and how HPVs may be involved in cSCCs development in immunocompetent individuals, however, remains a matter of debate ([@B34]), even though a recent meta-analysis provided evidence for a modestly increased overall risk of 1.42 (1.18--1.72) for β-HPV infection and cSCC development ([@B17]).

Hence, β-HPV infections are highly associated with cSCC development in EV patients, correlated in the case of cSCCs arising in immune suppressed patients, and only slightly or sporadically associated with cSCCs in immune competent patients. HPV sequences are not retained and expressed in every cSCC cell. This indicates that, unlike what has been shown for high-risk α-HPV-associated cancers, cutaneous HPVs may not be necessary for tumor maintenance. Cutaneous HPV genomes are almost universally detected in asymptomatic patients ([@B4]; [@B60]), but it is not clear whether this is reflective of active and/or persistent infection. Detection of HPV RNA or protein expression may provide a better estimation of the frequency of active HPV infection in non-neoplastic skin ([@B11], [@B10]) and it has been debated whether cutaneous HPVs function as carcinogenic drivers, or if they appear as innocuous passengers in cSCCs that arise in immunocompetent individuals ([@B93]). A recent study with a transgenic mouse model, has provided evidence for the alternative model that some cutaneous HPVs are drivers of cancer initiation but are not necessary for tumor maintenance ([@B114]).

Carcinogenic Activities of β-HPVs
=================================

Because of their isolation from cSCCs in EV patients, much of the early research efforts with the β-HPVs focused on HPV5 and HPV8. Somewhat surprisingly, HPV5 and HPV8 scored as only weakly transforming or non-transforming in standard cell-based assays ([@B131]; [@B108]). However, experiments with genetically engineered mice where HPV8 sequences were expressed in basal epithelial cells, impressively demonstrated the oncogenic activity of this HPV. While these mice spontaneously develop skin cancer without the requirement of any additional treatment, they also recapitulated the co-carcinogenic effect of UV exposure (reviewed in [@B49]). These experiments showed that HPV8 E6, E7 and, uniquely, also E2 could each independently contribute to skin cancer formation when ectopically expressed in basal epithelial cells of a transgenic mouse ([@B100]; [@B90]; [@B67]).

The β-HPVs are phylogenetically diverse and as of January 2018, 64 β-HPVs are listed in the PAVE database (see text footnote 1; [@B112]). These are further classified into phylogenetic species. HPV5 and HPV8 together with 19 additional HPVs are classified as species 1, there are 22 members classified as species 2, four are species 3, one is species 4, three are species 5, and 13 have not yet been classified by the HPV reference center.

The E6 and E7 proteins of other β-HPVs, including HPV types 20, 38, and 48 also exhibit carcinogenic activities in transgenic mouse models. Mice expressing β1-HPV20 E6 or E7 from keratin K10 promoter and mice with β2-HPV38 E6/E7 expression from a keratin K14 promoter developed skin cancers when exposed to UV. In contrast, mice expressing the β3-HPV49 E6/E7 genes from a keratin 14 promoter were not susceptible to skin carcinogenesis after UV exposure but developed upper digestive tract carcinomas when treated with the chemical carcinogen 4-nitroquinoline 1-oxide ([@B79]; [@B116], [@B117]). Some of these more recently detected β-HPVs also exhibit transforming activities in cell-based assays. Ectopic expression of the β1 HPV24 or HPV36 E6/E7 proteins causes life span extension of primary human foreskin keratinocytes (HFKs), whereas expression of the β2 HPV38 and β3 HPV49 E6/E7 proteins can trigger HFK immortalization ([@B26]).

Despite similar genomic organization, there are some differences between the β- and high-risk α-HPVs ([@B73]). Most strikingly, β-HPVs do not encode E5 proteins, which are oncogenic in high-risk α-HPVs ([@B40]; [@B71], [@B70]). Moreover, while high-risk α-HPV-associated cervical carcinomas are generally non-productive, cSCCs arising in EV patients are productive infections. Despite these differences, early mechanistic analyses of the oncogenic activities of β-HPVs were modeled after studies with high-risk α-HPV E6 and E7 proteins. Like high-risk α-HPV E6 and E7 proteins, β-HPV E6 and E7s are low molecular weight, cysteine-rich, metal binding proteins of approximately 150 and 100 amino acids, respectively. They lack intrinsic enzymatic activities, are not known to directly bind specific DNA sequences and presumably exert their biological activities by interacting with and functionally modifying cellular regulatory proteins ([@B82]; [@B97]; [@B113]). The best studied cellular targets of the high-risk α-HPV E6 and E7 proteins are the TP53 and RB1 tumor suppressors, respectively. The transforming activities of papillomaviruses are a reflection of their life cycles, specifically their need to secure the availability of cellular replication factors in terminally differentiated epithelial cells that would have normally withdrawn from the cell division cycle ([@B46]). Papillomaviruses need to uncouple cell-cycle withdrawal from epithelial differentiation, effectively allowing for unlicensed proliferation in suprabasal keratinocytes. Aberrant DNA synthesis can be sensed by cells and triggers cell abortive responses, which will need to be inhibited by the virus. The strategies that specific papillomaviruses have evolved to enable their productive replication cycles largely determine their oncogenic potential ([@B74]; [@B81]).

The high-risk HPV E7 proteins cause S-phase competence in differentiating cells by targeting the retinoblastoma tumor suppressor, RB1, for degradation. Uncontrolled S-phase entry as a consequence of RB1 inactivation causes activation of the TP53 tumor suppressor, which triggers a transcriptional program to eliminate such rogue cells by apoptosis. This simple, albeit likely not entirely correct, model ([@B82]; [@B83]) also served as a blueprint for many studies with the EV-associated β-HPVs, even though it became clear very quickly that it was unlikely to apply to these viruses ([@B73]; [@B76]; [@B108]). HPV8 E6 does not detectably interact with TP53 or the UBE3A (E6AP) E3 ubiquitin ligase that is necessary for high-risk α-HPV E6 mediated TP53 degradation ([@B33]; [@B126]; [@B13]). HPV5 and HPV8 E7s weakly bind and do not degrade RB1, similar to the low-risk α-HPV E7s ([@B131]).

All known β-HPV E7 proteins contain canonical LXCXE (L, leucine; C, cysteine; E, glutamate; X, any amino acid)-based binding sites for the retinoblastoma tumor suppressor family of proteins and many have been documented to bind RB1, RBL1 (p107), and RBL2 (p130). Some β-HPV E6 and E7 in fact interfere with RB1 and TP53 stability, reminiscent of cervical cancer associated, high-risk α-HPVs ([@B15]; [@B1]; [@B26]; [@B128]). The interactions described for β-HPV E6 proteins with TP53 are particularly complex as some have been reported to stabilize TP53 (HPV17, HPV38, and HPV92), while others destabilize it (HPV49) and some have been reported to interfere with TP53 activation and/or TP53 mediated activation of certain target genes (HPV5, HPV8, and HPV38) ([@B26]; [@B118]; [@B128]). Whether humans infected with cutaneous HPVs that target RB1 and TP53 similar to the high-risk α-HPVs are at a particularly high risk for developing cSCC, remains to be determined.

Given the fact that most β-HPV-associated tumors arise in sun exposed areas, it was investigated whether these viruses might interfere with UV-induced apoptosis and/or DNA damage repair. Consistent with expectations, several groups reported that β-HPV E6 proteins cause degradation of BAK, a pro-apoptotic BCL2 family member that is released from the mitochondria following UV exposure ([@B55]). BAK degradation by β-HPV E6 proteins is predicted to inhibit apoptosis and allow for survival of UV-damaged cells that may have possibly acquired oncogenic mutations ([@B65]; [@B52]).

Other studies showed that the repair of UV-damaged DNA damage is inhibited in HPV8 E6 expressing cells. HPV5 and HPV8 E6 proteins were reported to bind the EP300/CREBBP acetyltransferases and target them for degradation thereby inhibiting the Ataxia Telangiectasia Mutated (ATM) and Ataxia Telangiectasia and Rad3-Related (ATR) kinases, key sensors, and mediators of double strand DNA break repair. By abrogating ATM/ATR mediated sensing and/or repair of double strand DNA breaks, cellular mutations may accumulate in β-HPV infected cells, thereby driving carcinogenesis ([@B48]; [@B119]; [@B123]). These findings support a "hit-and-run" mechanism for β-HPV carcinogenesis where viral gene expression contributes to cancer initiation by increasing the mutational burden caused by UV exposure but is not necessary for tumor maintenance. This would explain why viral gene expression is not maintained in all tumor cells ([@B6]). Such a model was recently recapitulated with HPV38 transgenic mice ([@B115]). Interestingly, unbiased proteomic analyses of the HPV38 E6 associated proteins provided no evidence for EP300/CREBBP binding to HPV38 E6 ([@B126]), suggesting that inhibition of DNA break repair by β-HPV E6 proteins may not be necessarily linked to EP300/CREBBP degradation.

As mentioned previously, β-HPV genomes have been detected in hair follicles, which contain epithelial stem cells and HPV8 has been reported to increase the number of keratinocytes with stem cell characteristics both in cell- and animal-based model systems ([@B51]; [@B63]; [@B68]). Several studies have shown that the TP53 family member and epithelial stem cell marker TP63 is dysregulated in HPV8 E6 expressing keratinocytes. Specifically, higher levels of the amino terminally truncated ΔNp63α and lower levels of full-length TAp63 isoforms were detected in HPV8 E6 expressing human and murine keratinocytes ([@B63]; [@B68]). NOTCH inhibition decreased TP63 levels in HPV8 E6 expressing undifferentiated keratinocytes, but TP63 expression remained high in differentiating HPV8 E6 expressing keratinocytes, suggesting that there are NOTCH independent pathways that cause deregulated TP63 expression ([@B77]). One of these pathways involves down-regulation of microRNA-203 (miR-203) by HPV8 E6 by inhibiting EP300 which in turn affects CCAAT/enhancer-binding protein a (CEBPA) transcription factor activity that controls miR-203 expression. Significantly, up-regulation of miR-203 during calcium-induced differentiation is abrogated in HPV8 E6 expressing keratinocytes ([@B68]). High-level TP63 and low levels of miR-203 were also detected throughout the lesional tissue of an HPV8 positive EV patient ([@B68]). Since EP300 binding is not shared by all β-HPV E6 ([@B126]) it remains to be determined whether this pathway is universally targeted by β-HPV E6 proteins.

The γ-HPVs; Benign Flora or Dangerous Villains?
===============================================

As of January 2018, a total of 171 γ-HPVs have been detected, which are classified into 27 different species. The number of species may increase, since 93 γ-HPVs have not yet been classified into species by the HPV reference center (see text footnote 1; [@B112]). The enormous phylogenetic diversity of γ-HPVs is also reflected in their genome organization; members of the γ6 species, for example, do not encode recognizable E6 proteins and some γ-HPVs encode E7 proteins that lack the canonical LXCXE binding site for the RB1 tumor suppressor and the related p107 (RBL1) and p130 (RBL2) proteins. The γ-HPVs were initially isolated from cutaneous epithelia and are often regarded as components of the normal skin viral flora ([@B4],[@B5]; [@B36]; [@B20]; [@B37]). More recent studies also detected γ-HPV DNA at mucosal sites ([@B12]; [@B104]).

A "deep sequencing" study of human skin cancers and matched normal tissues showed that HPV197, a γ24-HPV, was the most frequently detected HPV genome in cSCCs and was not present in normal skin ([@B7]). HPV197 could not have been previously detected because the genome is not recognized by the "consensus" PCR primers that are frequently used for HPV analysis of clinical specimens ([@B7]). To this date, however, there is no evidence that HPV197 sequences are actively expressed in skin cancers and/or that HPV197 or potentially other γ-HPVs contribute to cSCC development in immunosuppressed or immunocompetent individuals.

Analysis of potential cellular targets by affinity purification followed by mass spectrometry (AP/MS) revealed that HPV197 E6 shares many cellular targets with β-HPV E6 proteins, particularly the β1 HPVs that include HPV5 and HPV8 ([@B42]). The HPV197 E7 protein lacks an LXCXE-based RB1 binding site, yet, consistent with earlier work with the γ1 HPV4 E7 protein ([@B121]), HPV197 E7 interacts with RB1 ([@B42]). Interestingly, however, HPV197 E7 does not bind to RBL1 or RBL2 ([@B42]). The detection of HPV197 DNA in human skin cancers but not normal skin, and the interactions of the E6 and E7 proteins with human tumor suppressor proteins are consistent with the possibility that HPV197 and potentially other γ-HPVs may be associated with skin cancer development. Currently, however, only very few studies have explored the biological activities of γ-HPVs in cell-based or animal models.

MmuPV1, An Animal Model for Cutaneous HPV Infections
====================================================

Papillomaviruses are species specific and generally do not infect heterologous hosts ([@B59]). This has severely hindered the study of PV pathogenesis *in vivo*. Research has also been stymied by the lack of a papillomavirus that naturally infects and replicates in a genetically tractable laboratory animal. The isolation of *Mus musculus* papillomavirus 1, MmuPV1, from skin warts on immunodeficient nude mice promises to revolutionize PV pathogenesis studies ([@B53]; [@B57]). The ability to cause wart formation upon experimental infection with quasivirus or by naked DNA inoculation was originally observed in mouse strains that have T-cell deficiencies or are temporarily immune suppressed ([@B45]; [@B56]; [@B110]). Lesions arising due to MmuPV1 infection have malignant potential and can progress to cSCCs. Upon UVB-exposure, experimental MmuPV1 infection also causes skin warts that can progress to cSCCs in immunocompetent, standard laboratory mouse strains ([@B109]). Importantly, there is a correlation between immunosuppression due to UV irradiation and onset of MmuPV1 dependent cutaneous papillomas ([@B110]).

MmuPV1 is a member of the Pi genus, which encompasses rodent PVs ([@B112]) and is related to γ- and β-HPVs ([@B57]). Consistent with these phylogenetic relationships, the MmuPV1 E6 protein has similar cellular targets as the β-HPV8 E6 protein ([@B78]). The MmuPV1 E7 protein is related to the γ-HPV197 E7 protein in that it lacks the canonical LXCXE-based RB1 binding site ([@B57]; [@B42]). Moreover, transcriptomic analyses revealed that similar to cutaneous HPVs, MmuPV1 expresses E6 and E7 from two separate early promoters ([@B130]).

Because of its ability to infect cutaneous epithelia and cause lesions capable of malignant progression upon UV exposure, MmuPV1 may be an important model for determining the potential roles of β- and some γ-HPVs in skin cancer development.

Interestingly, MmuPV1 can productively infect both cutaneous and mucosal tissues ([@B24], [@B23]; [@B50]) and thus may also model aspects of mucosal pathogenesis. In any case, results from infection experiments with mutant MmuPV1 genomes can be combined with infection studies of relevant, genetically engineered mouse models. This will enable studies to define mechanisms of action of viral proteins and to determine how viral targeting of specific cellular signaling pathways contribute to the life cycle, pathogenesis and carcinogenicity of a papillomavirus in a natural host.

Subversion of TGF-β and Notch Signaling by Cutaneous Papillomaviruses
=====================================================================

While inhibition of UV-mediated apoptosis and/or DNA damage sensing/repair provides a satisfying model to mechanistically support a hit-and-run mechanism of cutaneous HPV mediated carcinogenesis, it does not explain how these viruses may cause warts, a necessary precursor to cSCCs. Moreover, studies with MmuPV1 showed that UV-mediated immune suppression rather than mutagenesis was important for pathogenesis and tumor development ([@B110]).

Inhibition of TGF-β Signaling
-----------------------------

Multiple developmental and cellular processes are regulated by TGF-β signaling. The core components of this signal transduction pathway consist of the ligand, TGF-β, heterotetrameric receptors with serine/threonine kinase activity, receptor associated SMAD (R-SMADs) proteins, and co-activator SMADs (co-SMADs). The tetrameric receptor consists of one dimer of the ligand interacting TGF-β type II receptor (TGFBR2), and one dimer of TGF-β type I receptor (TGFBR1). TGF-β binding triggers a phosphorylation cascade from TGFBR2 to TGFBR1 to R-SMADs ([@B18]). Activin/Nodal and TGFBR1 receptors phosphorylate the R-SMAD pair SMAD2 and SMAD3, whereas the Bone Morphogenetic Protein (BMP) type I receptors activate the R-SMADs SMAD1, SMAD5, and SMAD8 ([@B80]). After phosphorylation, R-SMADs complex with the co-SMAD, SMAD4, enter the nucleus, bind specific DNA sequences, and activate target gene transcription (**Figure [1A](#F1){ref-type="fig"}**). Transcriptional activation of the CDK2 inhibitors p21^CIP1^ (CDKN1A) and p27^KIP1^ (CDKN1B), and the CDK4/CDK6 inhibitor p15^INK4B^ (CDKN2B) have been linked to TGF-β mediated G1 cell cycle arrest ([@B27]; [@B95]). Hence, TGF-β functions as a tumor suppressor in epithelial cells, and TGF-β pathway loss of function mutations are frequent in epithelial tumors ([@B120]; [@B92]; [@B35]). Importantly, however, TGF-β signaling also induces expression of factors involved in epithelial to mesenchymal transition (EMT) and causes increased production of matrix metalloproteases, which results in enhanced migration and invasion ([@B111]). This is consistent with an oncogenic activity of TGF-β as was originally discovered in fibroblasts ([@B96]). Hence, the NOTCH and TGF-β signaling pathways each have tumor suppressor activities at early stages of carcinogenesis and can function as oncogenes during later stages of carcinogenesis.

![Subversion of TGF-β signaling by HPV8 and MmuPV1 E6. In normal cells, TGF-β binding to the heterotetrameric serine/threonine kinase receptor complex triggers a phosphorylation cascade resulting in phosphorylation of receptor the SMADs, SMAD2, and SMAD3. Phosphorylated receptor SMADs disassociate from the receptor, form a complex with the co-SMAD, SMAD4, and enter the nucleus. The SMAD2/SMAD3/SMAD4 complex then binds to SMAD binding sites to stimulate target gene transcription **(A)**. HPV8 and MmuPV1 E6 proteins bind SMAD2 and SMAD3 and inhibit TGF-β signaling by preventing the formation of the active DNA bound SMAD2/SMAD3/SMAD4 complex **(B)**.](fmicb-09-00389-g001){#F1}

The first evidence that cutaneous HPVs inhibit TGF-β signaling was provided by Michel Favre's group who reported that HPV5 E6 could target SMAD3 for proteasomal degradation ([@B75]). Consistent with this report, AP/MS experiments provided evidence for SMAD2 and SMAD3 association with HPV8 E6 ([@B78]). Similarly, the MmuPV1 E6 protein was also shown to bind SMAD2 and SMAD3 ([@B78]). Unlike many other papillomavirus E6 binding cellular proteins, SMAD2 and SMAD3 do not contain helical LXXLL (L, leucine; X, any amino acid) motifs ([@B21]). There is no evidence for SMAD2, SMAD3, or SMAD4 destabilization by HPV8 E6 or MmuPV1 E6 either under basal or TGF-β stimulated conditions ([@B78]). Moreover, there is no defect in SMAD2/SMAD3 phosphorylation and nuclear translocation following TGF-β stimulation in HPV8 or MmuPV1 E6 expressing human keratinocytes. The HPV8 and MmuPV1 E6 proteins, however, were shown to reduce SMAD4 association with SMAD2 and SMAD3 after TGF-β stimulation and to inhibit SMAD2/3 and SMAD4 binding to target DNA. Hence cutaneous papillomavirus E6 proteins inhibit TGF-β signaling by blocking productive binding of the SMAD2/3/4 complex to TGF-β responsive promoters ([@B78]; **Figure [1B](#F1){ref-type="fig"}**). It will be interesting to determine whether these E6 proteins can also inhibit signaling by TGF-β related cytokines. Interestingly, TGF-β signaling is also inhibited by α-HPVs and high-risk HPV16 has been reported to inhibit TGF-β through E7 ([@B91]; [@B64]) as well as E5 ([@B39]), but not through E6. Hence the cutaneous and mucosal HPVs share the ability to inhibit TGF-β signaling although they have evolved different mechanisms.

Inhibition of NOTCH Signaling
-----------------------------

Similar to TGF-β, NOTCH regulates multiple processes during embryogenesis and in the adult organism. Of particular interest to papillomavirus biology, NOTCH signaling drives epithelial differentiation and is required for proper formation of the skin barrier ([@B94]). NOTCH signaling is triggered through cell-to-cell contact where membrane anchored ligands of the Delta or Jagged family bind to NOTCH family receptors. In humans there are four NOTCH receptors (NOTCH1--4), which exhibit some overlapping functions, though this may be context specific ([@B61]). Receptor--ligand binding induces conformational changes in NOTCH that result in a series of proteolytic cleavages ultimately releasing an intracellular fragment of the NOTCH receptor, termed Intracellular NOTCH (ICN; [@B28]). ICN translocates to the nucleus where it associates with Recombination Signal Binding Protein for Immunoglobulin Kappa J Region (RBPJ), which binds to specific DNA sequences. In the absence of ICN, RBPJ is bound to the DNA in association with co-repressors, thus repressing target gene expression ([@B88]; **Figure [2A](#F2){ref-type="fig"}**). ICN displaces these co-repressors and the ICN--RBPJ complex recruits a member of the transcriptional co-activators mastermind-like (MAML) family ([@B84]). The ICN/RBPJ/MAML complex represents the core NOTCH transcriptional activator complex and MAML then recruits additional co-activators (**Figure [2B](#F2){ref-type="fig"}**; [@B99]). Classical NOTCH targets include the Hairy and Enhancer of Split (HES) gene, which belongs to a family of basic helix-loop-helix transcriptional repressors, which are particularly important for lateral inhibition and patterning during development ([@B54]). NOTCH also regulates other targets such as c-myc (MYC; [@B124]), cyclin D1 (CCND1; [@B25]), and the p21^CIP1^ (CDKN1A) cyclin dependent kinase inhibitor ([@B94]). Due to the variety of cell types where NOTCH signaling is important, NOTCH target genes are lineage specific and critical NOTCH targets that drive keratinocyte differentiation have not been well-characterized.

![Schematic of NOTCH target gene expression. In the absence of ligand binding, NOTCH responsive genes remain repressed and RBPJ is in a DNA bound, nuclear complex with repressors such as the N-CoR complex **(A)**. Ligand binding leads to NOTCH cleavage and ICN enters the nucleus, displaces repressors and recruits MAML and other co-activators such EP300/CREBBP **(B)**. HPV8 and MmuPV1 E6 proteins inhibit NOTCH signaling by forming a complex with the DNA bound ICN/MAML1 complex thereby preventing formation of a functional transcriptional activator complex **(C)**.](fmicb-09-00389-g002){#F2}

Human cSCCs frequently harbor loss of function mutations in the NOTCH pathway, implicating NOTCH activity as tumor suppressive in epithelial cells ([@B86]; [@B2]; [@B106]; [@B122]; [@B105]). The tumor suppressive effects of NOTCH in keratinocytes are largely thought to be due to a differentiation-induced block of cell proliferation and the activation of keratinocyte cell death ([@B133]; [@B8]). NOTCH, however, also functions as an oncogenic driver in a number of human tumors, particularly hematopoietic cancers such as T-cell acute lymphoblastic leukemia (T-ALL) where gain of function mutations are commonly observed ([@B31]).

MAML1 was originally identified in a yeast-two hybrid screen with HPV16 E6 as a bait ([@B129]). Like many cellular E6 binding proteins, MAML1 contains LXXLL sequence motifs and several groups detected MAML1 as a cellular interactor of β-HPV E6 proteins in AP/MS experiments ([@B14]; [@B98]; [@B107]; [@B126]). Similarly, the bovine papillomavirus type 1 (BPV1) E6 protein was also shown to bind MAML1 ([@B14]; [@B107]). Despite the original identification as an HPV16 E6 associated cellular protein ([@B129]), there is no evidence that mucosal α-HPV E6 proteins detectably associate with MAML1 in mammalian cells ([@B13]).

Biological Consequences of TGF-β and NOTCH Inhibition by Cutaneous Papillomaviruses
-----------------------------------------------------------------------------------

Given that the TGF-β and NOTCH pathways are critical in regulating epithelial differentiation and function as tumor suppressors in a variety of epithelial cancers, inhibition of these two pathways by cutaneous papillomavirus E6 proteins may be key to the transforming activities of these viruses.

Consistent with this model, it was shown that keratinocyte differentiation is inhibited in HPV8 E6 expressing epithelial cells. Chromatin immunoprecipitation experiments showed that E6 binds to and inhibits the DNA bound RBPJ/ICN/MAML1 activator complex ([@B77]). HPV8 E6 binds to an LXXLL motif within the C-terminal transactivation domain (TAD) 2 of MAML1 ([@B107]; [@B78]). The mechanism of action of TAD2 is unknown; EP300 and related co-activators associate with MAML through its TAD1 domain ([@B99]; [@B41]). The MmuPV1 E6 protein also interacts with MAML1 and inhibits NOTCH signaling thereby inhibiting keratinocyte differentiation ([@B78]; **Figure [2C](#F2){ref-type="fig"}**). MAML1 binding defective HPV8 and MmuPV1 E6 mutants were identified using a structure guided approach ([@B78]). Of note, many of the HPV8 E6 mutants that were previously used to characterize the biological relevance of the interaction between cutaneous HPV E6 protein and EP300/CREBBP, were found to be MAML1 binding defective, thus further complicating the interpretation of published studies investigating the biological consequences of the EP300/CREBBP interactions with HPV5 and HPV8 E6 ([@B78]). Association of E6 with MAML and inhibition of NOTCH signaling is independent of EP300/CREBBP binding, however, since MAML1 binding defective HPV8 E6 mutants retained EP300/CREBBP association and MmuPV1 E6 does not detectably bind EP300/CREBBP ([@B78]). Indeed, the notable absence of EP300/CREBBP peptides in AP/MS experiments with MmuPV1 E6 is consistent with a model whereby E6 binding to TAD2 of MAML1 may inhibit expression of NOTCH transcriptional targets by interfering with recruitment or by displacing EP300/CREBBP from MAML1 TAD1. This model, however, awaits experimental validation.

The presence of an intact binding site for MAML1 in MmuPV1 E6 was shown to be necessary for formation of papillomas and carcinomas in experimentally infected mice ([@B78]). While these studies cannot definitively exclude the possibility that association of E6 with other LXXLL domain proteins may also contribute to this phenotype, this is unlikely given a recent study that showed that UBE3A and MAML1 are the major LXXLL targets of papillomavirus E6 proteins and, consistent with the published E6/LXXLL structures ([@B132]), the various papillomavirus E6 proteins displayed mutually exclusive binding to either UBE3A or MAML1 ([@B13]).

Despite the fact that the E6 proteins of mucosal, high-risk α-HPVs have a strong preference for UBE3A binding and do not detectably interact with MAML1 ([@B126]; [@B13]), they have also been reported to inhibit NOTCH. HPV16 E6 can inhibit NOTCH signaling indirectly through degradation of the TP53 tumor suppressor ([@B32]) and/or the TAp63β protein ([@B9]). More recent studies showed that NOTCH inhibition is relevant to the biology of these viruses as HPV16 E6 mediated NOTCH inhibition was shown to decrease the commitment of keratinocytes to differentiation ([@B62]).

Hence, similar to TGF-β, inhibition of keratinocyte differentiation by targeting NOTCH signaling by cutaneous HPVs is shared with mucosal HPVs but is mediated through different mechanisms. Conceptually this is rather satisfying as papillomaviruses all had to evolve to render normally postmitotic, terminally differentiated epithelial cells conducive for supporting the viral life cycle (**Figure [3](#F3){ref-type="fig"}**). Interestingly however, different papillomaviruses have evolved mechanistically distinct strategies to solve this problem.

![Functional consequences of NOTCH and TGF-β signaling by HPV8 E6 and MmuPV1 E6. TGF-β and NOTCH signaling are critical for cell cycle arrest and keratinocyte differentiation that are tightly coupled in normal squamous epithelial cells. Functional uncoupling of these two processes is a necessary prerequisite for papillomavirus progeny formation in terminally differentiated epithelial cells.](fmicb-09-00389-g003){#F3}

"Hit and Run" Carcinogenesis: A Consequence of E6 Mediated NOTCH and TGF-β Inhibition?
--------------------------------------------------------------------------------------

Hit and run carcinogenesis is a concept that historically has generated some skepticism, also with the authors of this article. The failure to detect viral gene expression in the majority of cancer cells may also imply that β- and γ-HPVs are biologically innocuous passengers that do not drive the carcinogenic process. Given, however, that at least some of these papillomaviruses are carcinogenic in transgenic mouse models and inhibit TGF-β and NOTCH signaling as well as other tumor suppressor pathways, it is more likely that these viruses provide oncogenic hits that drive at least some early aspects of epithelial carcinogenesis. In addition to many other biological activities of cutaneous HPVs, which include stem cell expansion, abrogating apoptosis, sensing and repair of UV-induced double strand DNA breaks, inhibition of the TGF-β and NOTCH tumor suppressors provide plausible oncogenic "hits" during early phases of carcinogenesis. Since the NOTCH and TGF-β pathways are oncogenic at later stages and drive malignant progression ([@B69]; [@B8]) loss of papillomavirus gene expression will re-activate NOTCH and TGF-β. This may drive malignant progression, thereby providing the mechanistic underpinnings for the "run" component of hit and run carcinogenesis.

It is important to note that the β- and γ-HPVs are phylogenetically and biologically diverse ([@B26]; [@B112]) and that this diversity is also reflected in the cellular interactomes of their E6 and E7 proteins ([@B126],[@B127]). Hence, findings with one specific β- or γ-HPV type may not be applicable to other HPVs, even within the same genus. The accumulation of UV-induced mutations in a recently published HPV38 transgenic skin cancer model that recapitulates hit-and-run carcinogenesis, for example, is unlikely to be caused through an EP300/CREBBP dependent mechanism as no EP300/CREBBP binding has been detected in unbiased AP/MS studies with HPV38 E6 ([@B126]; [@B115]).

The wide application of AP/MS to define cellular interactomes of papillomavirus proteins has already generated interesting hypotheses, many of which await rigorous validation ([@B125]; [@B72]). Next generation sequencing experiments may detect HPV DNA and/or RNA sequences in unexpected anatomic locations and tentatively link them to unanticipated pathologies ([@B19]). Such studies may also lead to the identification of HPVs that evaded detection by standard PCR-based techniques. The frequent detection of the novel γ-HPV197 genome in a deep sequencing study of human skin cancers, but not in normal skin, while not implying an etiologic link, should provide at least an impetus to study the biology of γ-HPVs in greater detail ([@B7]). Given that the HPV197 E7 protein, similar to MmuPV1, lacks an LXCXE-based canonical RB1 binding domain, and binds RB1 through a different sequence, suggest that some aspects of HPV197 E7 can be studied with the MmuPV1 animal model. These and other studies might also reveal whether HPV197, and potentially other γ-HPVs, have oncogenic activities.
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